Executive Moves
Eye hospital group Optegra has appointed Melanie Andrew as its first NHS commissioning director.
OpthalmologyCategory: Opthalmology
Executive Moves
Executive Moves
Eye hospital group Optegra has appointed Adam Cockley as commercial director in its UK leadership team.
Opthalmology
News
London based ophthalmic gene therapy company Beacon Therapeutics has raised $170m to advance development of gene therapies.
Fundraising
News
Specialist eye hospital group Optegra is launching a series of NHS cataract diagnostic clinics.
Opthalmology
Executive Moves
London-based independent eye surgery provider OCL Vision has appointed Nik Rudge as chief executive.
Opthalmology
News
US pharmaceutical firm Merck has acquired Eyebiotech Limited (EyeBio), a London-based ophthalmology focused biotech company.
M&A
Executive Moves
Specialist eye hospital group Optegra has appointed Chris Chisholm as clinical services director.
Opthalmology
Executive Moves
Optegra Eye Health Care has appointed consultant ophthalmic surgeon Mike Adams as its national NHS training lead.
Opthalmology
News
Cataract surgery products company Rayner is acquiring Swiss-based This AG, the inventor, developer and manufacturer of Sophi phaco emulsification machines.
M&A
News
OCL Vision has invested half a million pounds in the introduction of SmartSight, a laser eye surgery procedure.
Opthalmology
News
Eye surgery provider OCL Vision invested approximately £2 million in the new clinic with funding support from HSBC.
Opthalmology
News
OCL Vision, a UK-based chain of eye surgery clinics, has partnered with Compucare, a Streets Heaver’s Patient Administration System (PAS), and Electronic Health Record (EHR).
News
MidEuropa has entered into a definitive agreement to acquire a majority stake in Optegra from current sponsor H2 Equity Partners.
Opthalmology
News
The sale process of Optegra by H2 Equity has been stalled, this publication hears from two advisory sources.
Opthalmology
News
The sale of Optegra by sponsor H2 Equity Partners has already moved into the second round, HealthInestor hears from sources close to the process.
Health Investor Report